New treatment options for atypical hemolytic uremic syndrome with the complement inhibitor eculizumab.
about
Atypical hemolytic uremic syndromeEculizumab for dense deposit disease and C3 glomerulonephritisAtypical haemolytic uraemic syndrome with underlying glomerulopathies. A case series and a review of the literatureMembranoproliferative glomerulonephritis and C3 glomerulopathy: resolving the confusionPandemic H1N1 influenza A viral infection complicated by atypical hemolytic uremic syndrome and diffuse alveolar hemorrhage.Age-related penetrance of hereditary atypical hemolytic uremic syndrome.Idiopathic combined, autoantibody-mediated ADAMTS-13/factor H deficiency in thrombotic thrombocytopenic purpura-hemolytic uremic syndrome in a 17-year-old woman: a case report.A prevalent C3 mutation in aHUS patients causes a direct C3 convertase gain of function.Thrombotic microangiopathy and associated renal disorders.Neonatal onset atypical hemolytic uremic syndrome successfully treated with eculizumab.Eculizumab for atypical hemolytic uremic syndrome recurrence in renal transplantation.Use of eculizumab for atypical haemolytic uraemic syndrome and C3 glomerulopathies.Complement therapy in atypical haemolytic uraemic syndrome (aHUS).Renal function in normal and disordered pregnancyAn international consensus approach to the management of atypical hemolytic uremic syndrome in children.Current evidence on the discontinuation of eculizumab in patients with atypical haemolytic uraemic syndrome.Eculizumab and recurrent C3 glomerulonephritisPathogenesis of the C3 glomerulopathies and reclassification of MPGN.Atypical Hemolytic Uremic Syndrome: Differential Diagnosis from TTP/HUS and Management.Treatment of atypical uraemic syndrome in the era of eculizumabA case of atypical hemolytic uremic syndrome associated with the c.1273C>T mutation in the complement C3 gene.Atypical hemolytic uremic syndromeThrombotic microangiopathies
P2860
Q21202864-8F1E65F2-BF53-4184-8291-F3947B6B2BD1Q24632330-81AFE962-0D5E-4A36-962E-E65588C3A149Q26864297-672EB632-DF13-414A-BDC5-6385A91386A5Q27008508-2D78EAD1-0665-4223-8DFF-A984BD2A0661Q30405809-FF61986B-2272-414A-8322-76DE693A77BEQ33397115-2DFE7631-F5CE-4195-9ACD-F094D165AE17Q33398967-BDD3CEFE-5E81-46B9-BD7D-73C3E74538C2Q33399198-7542BA28-6DD5-4B9C-9734-F4920E269869Q33402372-A6E63250-F120-46E3-BF99-3BC1F8F3FFB0Q33403172-28DE8D68-BDEA-4006-8280-8BC344252E33Q33403196-1D53B7C7-334B-4CCD-AFC5-477CAD0899D5Q33403607-0D2B4CF8-5475-45C4-B250-3BEC7F0C3531Q33408733-627E1F69-0329-4C90-864A-96921DD8DF88Q33411571-B606A1AE-93BB-4D7D-A0D3-5B3D2A6197EBQ33421861-764DA33A-3CA4-4019-A4FD-D49D94D791AFQ33783126-8B4FB051-4EA3-4D66-9687-1E2A3E291BABQ35597310-30FFBED6-6EE3-433F-A56E-07303AFC6CE4Q38048606-D034BDCF-CA71-4EE3-B036-1C9BD2D1909CQ39112532-306C1DF4-0503-43A5-A58A-F88EFC08CED1Q39719068-BBAB1DF1-E918-4BA6-AEB4-EFCA2C0A6F16Q41359309-E062E504-9A50-4721-AF8C-A366CDE32910Q56591965-C2797FF1-7CF7-415B-9CD3-5EE55C08ED23Q58690782-B2FA6421-EACE-44D7-8496-92FD3AB9B850
P2860
New treatment options for atypical hemolytic uremic syndrome with the complement inhibitor eculizumab.
description
2010 nî lūn-bûn
@nan
2010 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
New treatment options for atyp ...... mplement inhibitor eculizumab.
@ast
New treatment options for atyp ...... mplement inhibitor eculizumab.
@en
type
label
New treatment options for atyp ...... mplement inhibitor eculizumab.
@ast
New treatment options for atyp ...... mplement inhibitor eculizumab.
@en
prefLabel
New treatment options for atyp ...... mplement inhibitor eculizumab.
@ast
New treatment options for atyp ...... mplement inhibitor eculizumab.
@en
P2093
P356
P1476
New treatment options for atyp ...... mplement inhibitor eculizumab.
@en
P2093
Christoph Mache
Jens Nürnberger
Lothar-Bernd Zimmerhackl
Ozlem Köse
Therese Jungraithmayr
P304
P356
10.1055/S-0030-1262889
P577
2010-09-23T00:00:00Z